The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Blocking CGRP in migraine patients – a review of pros and cons
Open accessAbstract
Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have been developed: small molecule CGRP receptor antagonists (gepants), and monoclonal antibodies, targeting either CGRP or the CGRP receptor. Several trials have been conducted to test the efficacy and safety of these drugs. In general, a superior efficacy compared to placebo has been shown, especially with regards to the antibodies. In addition, the efficacy is in line with other currently used prophylactic treatments. The drugs have also been well tolerated, except for some of the gepants, which induced a transient increase in transaminases. Thus, blocking CGRP in migraine patients is seemingly both efficient and well tolerated. However, CGRP and its receptor are abundantly present in both the vasculature, and in the peripheral and central nervous system, and are involved in several physiological processes. Therefore, blocking CGRP may pose a risk in subjects with comorbidities such as cardiovascular diseases. In addition, long-term effects are still unknown. Evidence from animal studies suggests that blocking CGRP may induce constipation, affect the homeostatic functions of the pituitary hormones or attenuate wound healing. However, these effects have so far not been reported in human studies. In conclusion, this review suggests that, based on current knowledge, the pros of blocking CGRP in migraine patients exceeds the cons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
Russell, F. A., King, R., Smillie, S.-J., Kodji, X., & Brain, S. D. (2014) · Physiological Reviews · doi:10.1152/physrev.00034.2013 · Cited by 1,258
Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
Olesen, J., Diener, H.-C., Husstedt, I. W., Goadsby, P. J., Hall, D., Meier, U., Pollentier, S., & Lesko, L. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030505 · Cited by 1,189
Goadsby, P. J., & Edvinsson, L. (1993) · Annals of Neurology · doi:10.1002/ana.410330109 · Cited by 1,158
Self-citationCgrp May Play A Causative Role in Migraine
Lassen, L., Haderslev, P., Jacobsen, V., Iversen, H., Sperling, B., & Olesen, J. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00310.x · Cited by 1,027
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
Tepper, S., Ashina, M., Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D., & Lenz, R. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30083-2 · Cited by 722
Topiramate for Migraine Prevention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Brandes, J. L. (2004) · JAMA · doi:10.1001/jama.291.8.965 · Cited by 653
Iyengar, S., Ossipov, M. H., & Johnson, K. W. (2017) · Pain · doi:10.1097/j.pain.0000000000000831 · Cited by 584
Diener, H.-C., Bussone, G., Oene, J. V., Lahaye, M., Schwalen, S., & Goadsby, P. (2007) · Cephalalgia · doi:10.1111/j.1468-2982.2007.01326.x · Cited by 561
Ho, T. W., Ferrari, M. D., Dodick, D. W., Galet, V., Kost, J., Fan, X., Leibensperger, H., Froman, S., Assaid, C., Lines, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61626-8 · Cited by 531
Topiramate in Migraine Prevention: Results of a Large Controlled Trial
Silberstein, S. D. (2004) · Archives of Neurology · doi:10.1001/archneur.61.4.490 · Cited by 529
Calcitonin gene-related peptide: functional role in cerebrovascular regulation.
McCulloch, J., Uddman, R., Kingman, T. A., & Edvinsson, L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.15.5731 · Cited by 514
Self-citationSilberstein, S. D., Lipton, R. B., Dodick, D. W., Freitag, F. G., Ramadan, N., Mathew, N., Brandes, J. L., Bigal, M., Saper, J., Ascher, S., et al. (2007) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00684.x · Cited by 497
Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist
Doods, H., Hallermayer, G., Wu, D., Entzeroth, M., Rudolf, K., Engel, W., & Eberlein, W. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703110 · Cited by 466
Ho, T. W., Mannix, L. K., Fan, X., Assaid, C., Furtek, C., Jones, C. J., Lines, C. R., & Rapoport, A. M. (2008) · Neurology · doi:10.1212/01.wnl.0000286940.29755.61 · Cited by 464
Adherence to oral migraine-preventive medications among patients with chronic migraine
Hepp, Z., Dodick, D. W., Varon, S. F., Gillard, P., Hansen, R. N., & Devine, E. B. (2015) · Cephalalgia · doi:10.1177/0333102414547138 · Cited by 433
Uddman, R., Edvinsson, L., Ekman, R., Kingman, T., & McCulloch, J. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90296-4 · Cited by 408
Self-citationDodick, D. W., Goadsby, P. J., Silberstein, S. D., Lipton, R. B., Olesen, J., Ashina, M., Wilks, K., Kudrow, D., Kroll, R., Kohrman, B., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70209-1 · Cited by 372
Dodick, D. W., Goadsby, P. J., Spierings, E. L. H., Scherer, J. C., Sweeney, S. P., & Grayzel, D. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70128-0 · Cited by 368
Sun, H., Dodick, D. W., Silberstein, S., Goadsby, P. J., Reuter, U., Ashina, M., Saper, J., Cady, R., Chon, Y., Dietrich, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00019-3 · Cited by 358
Diener, H.-C., Tfelt-Hansen, P., Dahl�f, C., L�inez, M. J. A., Sandrini, G., Wang, S.-J., Neto, W., Vijapurkar, U., Doyle, A., Jacobs, D., et al. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0464-6 · Cited by 343
Systematic Review of Migraine Prophylaxis Adherence and Persistence
Hepp, Z., Bloudek, L. M., & Varon, S. F. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.1.22 · Cited by 333
Mulderry, P. K., Ghatki, M. A., Spokks, R. A., Jonhs, P. M., Pierson, A. M., Hamid, Q. A., Kanse, S., Amara, S. G., Burrik, J. M., Legon, S., et al. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90018-8 · Cited by 333
Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects
Uddman, R., Edvinsson, L., Ekblad, E., Håkanson, R., & Sundler, F. (1986) · Regulatory Peptides · doi:10.1016/0167-0115(86)90071-6 · Cited by 323
Self-citationMarcus, R., Goadsby, P. J., Dodick, D., Stock, D., Manos, G., & Fischer, T. Z. (2014) · Cephalalgia · doi:10.1177/0333102413500727 · Cited by 296
Bigal, M. E., Dodick, D. W., Rapoport, A. M., Silberstein, S. D., Ma, Y., Yang, R., Loupe, P. S., Burstein, R., Newman, L. C., & Lipton, R. B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00249-5 · Cited by 287
Migraine and risk of cardiovascular disease in women: prospective cohort study
Kurth, T., Winter, A. C., Eliassen, A. H., Dushkes, R., Mukamal, K. J., Rimm, E. B., Willett, W. C., Manson, J. E., & Rexrode, K. M. (2016) · BMJ · doi:10.1136/bmj.i2610 · Cited by 286
Eftekhari, S., Salvatore, C. A., Johansson, S., Chen, T.-B., Zeng, Z., & Edvinsson, L. (2015) · Brain Research · doi:10.1016/j.brainres.2014.11.031 · Cited by 263
Self-citationHewitt, D. J., Aurora, S. K., Dodick, D. W., Goadsby, P. J., Ge, Y. (., Bachman, R., Taraborelli, D., Fan, X., Assaid, C., Lines, C., et al. (2011) · Cephalalgia · doi:10.1177/0333102411398399 · Cited by 263
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Ho, T. W., Connor, K. M., Zhang, Y., Pearlman, E., Koppenhaver, J., Fan, X., Lines, C., Edvinsson, L., Goadsby, P. J., & Michelson, D. (2014) · Neurology · doi:10.1212/wnl.0000000000000771 · Cited by 262
Self-citationBigal, M. E., Edvinsson, L., Rapoport, A. M., Lipton, R. B., Spierings, E. L. H., Diener, H.-C., Burstein, R., Loupe, P. S., Ma, Y., Yang, R., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00245-8 · Cited by 261
Self-citationEftekhari, S., Warfvinge, K., Blixt, F. W., & Edvinsson, L. (2013) · The Journal of Pain · doi:10.1016/j.jpain.2013.03.010 · Cited by 260
Self-citationCalcitonin gene-related peptide and pain: a systematic review
Schou, W. S., Ashina, S., Amin, F. M., Goadsby, P. J., & Ashina, M. (2017) · The Journal of Headache and Pain · doi:10.1186/s10194-017-0741-2 · Cited by 253
Voss, T., Lipton, R. B., Dodick, D. W., Dupre, N., Ge, J. Y., Bachman, R., Assaid, C., Aurora, S. K., & Michelson, D. (2016) · Cephalalgia · doi:10.1177/0333102416653233 · Cited by 247
Functional role of perivascular peptides in the control of cerebral circulation
Edvinsson, L. (1985) · Trends in Neurosciences · doi:10.1016/0166-2236(85)90050-5 · Cited by 233
Self-citationWiping Out CGRP: Potential Cardiovascular Risks
MaassenVanDenBrink, A., Meijer, J., Villalón, C. M., & Ferrari, M. D. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.002 · Cited by 232
Self-citationCGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment
Edvinsson, L. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12618 · Cited by 230
Self-citationRandomized, controlled trial of telcagepant for the acute treatment of migraine
Connor, K. M., Shapiro, R. E., Diener, H. C., Lucas, S., Kost, J., Fan, X., Fei, K., Assaid, C., Lines, C., & Ho, T. W. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b87942 · Cited by 217
Diener, H.-C., Barbanti, P., Dahlöf, C., Reuter, U., Habeck, J., & Podhorna, J. (2011) · Cephalalgia · doi:10.1177/0333102410388435 · Cited by 214
A second trigeminal CGRP receptor: function and expression of the AMY 1 receptor
Walker, C. S., Eftekhari, S., Bower, R. L., Wilderman, A., Insel, P. A., Edvinsson, L., Waldvogel, H. J., Jamaluddin, M. A., Russo, A. F., & Hay, D. L. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.197 · Cited by 189
Self-citationM.D., P. D. G., & M.D., P. D. E. (1994) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.1994.hed3407394.x · Cited by 171
Roggenkamp, D., Köpnick, S., Stäb, F., Wenck, H., Schmelz, M., & Neufang, G. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.464 · Cited by 161
Zhang, L., Hoff, A. O., Wimalawansa, S. J., Cote, G. J., Gagel, R. F., & Westlund, K. N. (2001) · Pain · doi:10.1016/s0304-3959(00)00378-x · Cited by 156
Calcitonin Gene‐Related Peptide ( CGRP ) and Migraine Current Understanding and State of Development
BIGAL, M. E., Walter, S., & Rapoport, A. M. (2013) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12179 · Cited by 152
Hougaard, A., Amin, F. M., Christensen, C. E., Younis, S., Wolfram, F., Cramer, S. P., Larsson, H. B. W., & Ashina, M. (2017) · Brain · doi:10.1093/brain/awx089 · Cited by 131
New drugs in migraine treatment and prophylaxis: telcagepant and topiramate
Edvinsson, L. I., & Linde, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60323-6 · Cited by 130
Self-citationEdvinsson, L. I., Nilsson, E., & Jansen‐Olesen, I. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707134 · Cited by 126
Self-citationSalmon, A., Damaj, M. I., Marubio, L. M., Epping-Jordan, M. P., Merlo‐Pich, E., & Changeux, J. (2001) · Nature Neuroscience · doi:10.1038/86001 · Cited by 125
Benschop, R. J., Collins, E. C., Darling, R. J., Allan, B. W., Leung, D., Conner, E. M., Nelson, J., Gaynor, B., Xu, J., Wang, X.-F., et al. (2014) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2014.01.009 · Cited by 125
Reinshagen, M., Flämig, G., Ernst, S., Geerling, I., Wong, H. H., Walsh, J. H., Eysselein, V. E., & Adler, G. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37636-0 · Cited by 124
Preventive treatment in migraine and the new US guidelines
Estemalik, E., & Tepper (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s33769 · Cited by 123
Migraine and the Risk for Stroke and Cardiovascular Disease
Sacco, S., & Kurth, T. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0524-1 · Cited by 122
Prophylaxis of migraine: general principles and patient acceptance
D’Amico, D., & Tepper, S. J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3497 · Cited by 116
Edvinsson, L. I., Mulder, H., Goadsby, P. J., & Uddman, R. (1998) · Journal of the Autonomic Nervous System · doi:10.1016/s0165-1838(98)00033-2 · Cited by 114
Self-citationTherapeutic antibodies against CGRP or its receptor
BIGAL, M. E., Walter, S., & Rapoport, A. M. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12591 · Cited by 110
Sensory Peptides as Neuromodulators of Wound Healing in Aged Rats
Khalil, Z. G., & Helme, R. D. (1996) · The Journals of Gerontology Series A · doi:10.1093/gerona/51a.5.b354 · Cited by 108
Possible sites of action of the new calcitonin gene-related peptide receptor antagonists
Eftekhari, S., & Edvinsson, L. I. (2010) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610388343 · Cited by 97
Self-citationOhno, T., Hattori, Y., Komine, R., Ae, T., Mizuguchi, S., Arai, K., Saeki, T., Suzuki, T., Hosono, K., Hayashi, I., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.10.001 · Cited by 95
Enteric and Visceral Afferent CGRP Neurons
Sternini, C. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb22766.x · Cited by 92
Mitsikostas, D. D., & Reuter, U. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000438 · Cited by 91
Mechanisms of Monoclonal Antibody–Drug Interactions
Zhou, H., & Mascelli, M. A. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100510 · Cited by 86
Long‐Term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized Trial
Connor, K. M., Aurora, S. K., Loeys, T., Ashina, M., Jones, C., Giezek, H., Massaad, R., Williams‐Diaz, A., Lines, C., & Ho, T. W. (2010) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01799.x · Cited by 84
Topiramate in Migraine Prevention
Silberstein, S. D. (2005) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2005.4501005.x · Cited by 80
Schankin, C. J., Maniyar, F., Seo, Y., Kori, S. H., Eller, M., Chou, D. E., Blecha, J. E., Murphy, S. T., Hawkins, R. A., Sprenger, T., et al. (2016) · Brain · doi:10.1093/brain/aww096 · Cited by 80
Randomized, controlled trial of telcagepant over four migraine attacks
Ho, A. P., Dahlöf, C. G. H., Silberstein, S. D., Saper, J. R., Ashina, M., Kost, J. T., Froman, S., Leibensperger, H., Lines, C. R., & Ho, T. W. (2010) · Cephalalgia · doi:10.1177/0333102410370878 · Cited by 75
Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice
Mishima, T., Ito, Y., Hosono, K., Tamura, Y., Uchida, Y., Hirata, M., Suzsuki, T., Amano, H., Kato, S., Kurihara, Y., et al. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00466.2010 · Cited by 69
Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease
Ho, T. W., Ho, A. P., CHAITMAN, B. R., Johnson, C. J., Mathew, N. T., Kost, J. T., Fan, X. F., Aurora, S. K., Brandes, J. L., Fei, K., et al. (2012) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2011.02052.x · Cited by 64
Wimalawansa, S. J., & El-Kholy, A. A. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90270-p · Cited by 56
Three-week neonatal hypoxia reduces blood CGRP and causes persistent pulmonary hypertension in rats
Keith, I. M., Tjen‐A‐Looi, S. C., Kraiczi, H., & Ekman, R. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.4.h1571 · Cited by 48
Calcitonin gene-related peptide and its specific binding sites in the cardiovascular system of rat
Wimalawansa, S. J., & MacIntyre, I. M. (1988) · International Journal of Cardiology · doi:10.1016/0167-5273(88)90313-0 · Cited by 46
Reduced responsiveness of cutaneous microcirculation in essential hypertension – A pilot study
Lindstedt, I., Edvinsson, M., & Evinsson, L. (2006) · Blood Pressure · doi:10.1080/08037050600996586 · Cited by 41
Multi-infarct dementia of Swedish type is caused by a 3’UTR mutation of COL4A1
Siitonen, M., Börjesson‐Hanson, A., Pöyhönen, M., Ora, A., Pasanen, P., Brás, J., Kern, S., Kern, J., Andersen, O., Stanescu, H. C., et al. (2017) · Brain · doi:10.1093/brain/awx062 · Cited by 41
Innervation of human epicardial coronary veins: immunohistochemistry and vasomotility
Opgaard, O. S., Gulbenkian, S., Anders Bergdahl, B., Barroso, C. P., Andrade, N., Polak, J. M., Melo, J. Q. E., & Edvinsson, L. I. (1995) · Cardiovascular Research · doi:10.1016/s0008-6363(96)88520-8 · Cited by 26
Self-citationCGRP antagonists and antibodies for the treatment of migraine
Vécsei, L., Szok, D., Csáti, A., & Tajti, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.960921 · Cited by 19
Barthó, L., Kóczán, G., & Maggi, C. A. (1993) · Neuropeptides · doi:10.1016/0143-4179(93)90051-b · Cited by 18
Cited by
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes
Kumari, S., Carmona, A. V., Tiwari, A. K., & Trippier, P. C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00530 · Cited by 654
Ferrari, M. D., Diener, H. C., Ning, X., Galic, M., Cohen, J. M., Yang, R., Mueller, M., Ahn, A. H., Schwartz, Y. C., Grozinski-Wolff, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31946-4 · Cited by 417
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 382
Advances in Meningeal Immunity
Rua, R., & McGavern, D. B. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.04.003 · Cited by 326
“This conclusion was based on experimental models of migraine, which showed nitric oxide donors, CGRP, and mast cellderived molecules (e.g., histamine, serotonin) all promote vasodilation [17, [96] [97] [98] [99] [100] [101] .”
Kynurenine Pathway of Tryptophan Metabolism in Migraine and Functional Gastrointestinal Disorders
Fila, M., Chojnacki, J., Pawlowska, E., Szczepanska, J., Chojnacki, C., & Blasiak, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810134 · Cited by 50
Metadata
- Authors
- On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS), Deen, M., Correnti, E., Kamm, K., Kelderman, T., Papetti, L., Rubio-Beltrán, E., Vigneri, S., Edvinsson, L., & Maassen Van Den Brink, A.
- Venue
- The Journal of Headache and Pain
- Published
- 2017-09-25
- Volume
- 18
- Issue
- 1
- Pages
- 96-96
- ISSN
- 1129-2369 (ISSN-L)
- 1129-2377
- OpenAlex
- W2757941745
- Cited by
- 298
- References
- 76
- FWCI
- 22.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.